ISRCTN36294212已完成不适用
Treatment of elderly patients with advanced chronic lymphocytic leukemia (CLL) with fludarabine versus chlorambucil
German CLL Study Group (GCLLSG)0 个研究点目标入组 200 人开始时间: 2005年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •2. Binet stage C or Binet stage B with symptoms, which require therapy, or Binet stage A with severe B-symptoms
- •3. Age 66 - 79 years
- •4. No previous treatment
- •5. Signed informed-consent
- •6. Life expectancy of more than six months
- •7. Eastern Cooperative Oncology Group (ECOG) status zero, one or two
排除标准
- •1. Severe organ dysfunction
- •2. Concomitant or previous neoplasm
研究者
相似试验
已完成
不适用
Therapeutic approach in elderly patients with polypharmacy by medical team: Prospective observational studyPolypharmacyJPRN-UMIN000024680ational Center for Geriatrics and Gerontology500
进行中（未招募）
不适用
Treatment protocol for elderly patients with mantle cell lymphoma (MCL). A phase II study of the Finnish Lymphoma Group.Mantle cell lymphomaEUCTR2004-003255-39-FIThe Finnish Lymphoma group30
已完成
4 期
Minimal-invasive treatment of geriatric patients with fragility fracture of the pelvis - a midterm follow-upS32Fracture of lumbar spine and pelvisDRKS00021470Abteilung für Unfallchirurgie, Orthopädie, Plastische und Handchirurgie; Universitätsklinikum Augsburg154
进行中（未招募）
不适用
Curative and palliative treatment of adults aged > 60 years with AML.A randomised trial by OSHO on the role of (1) early intensification {OSHO protocol} vs. common standard arm of German AML Intergroup Study, (2) allografting as consolidative immunotherapy vs. a second consolidation course in elderly patients,(3) prospective evaluation of the decision between curative and palliative treatment-intention. - AML 2004 OSHO #069Acute myelogenous leukemiaEUCTR2005-002833-10-ATGerman Competence network Acute and Chronic Leukemias” sponsored by Federal Ministry of Education a330
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.EUCTR2016-002272-27-BESaarland University388